Lenalidomide-prednisone induction followed by lenalidomide-melphalan- prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients

Leukemia

Volumn 27, Issue 3, 2013, Pages 695-701

  Falco, P ^a   Cavallo, F ^b   Larocca, A ^b   Rossi, D ^c   Guglielmelli, T ^d   Rocci, A ^b   Grasso, M ^e   Siez, M L M ^f   De Paoli, L ^c   Oliva, S ^b   Molica, S ^g   Mina, R ^b   Gay, F ^b   Benevolo, G ^h   Musto, P ⁱ   Omede P ^b   Freilone, R ^a   Bringhen, S ^b   Carella, A M ^j   Gaidano, G ^c   Boccadoro, M ^b   Palumbo, A ^b   more..

^a Division of Transfusional Medicine and Hematology   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f OSPEDALE DEGLI INFERMI   (Italy)

^g AO Pugliese Ciaccio ^*  (Italy)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

elderly patients; lenalidomide; melphalan; myeloma; unfit patients

Indexed keywords

LENALIDOMIDE; MELPHALAN; PREDNISONE;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MALE; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; SURVIVAL RATE; THALIDOMIDE;

EID: 84875218691     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.271     Document Type: Article

References (28)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W et al. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute: Bethesda, MD (http://seer.cancer.gov/csr/1975-2007/; based on November 2009 SEER data submission, posted to the SEER website, 2010).
2. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993-1999.
3. Brenner H, Gondos A, Pulte D. Recent major improvements in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
4. Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010; 46: 160-169.
5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
6. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV et al. Personalized therapy in multiple myeloma according to patients age and vulnerability: a report of the European Multiple Myeloma Network (EMN). Blood 2011; 118: 4519-4529.
7. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M et al. Thalidomide for previously untreated elderly patients with multiple myeloma: metaanalysis of 1685 individual patient data from six randomized clinical trials. Blood 2011; 118: 1239-1247.
8. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
9. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
10. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552.
11. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
12. Gay F, Haymann SR, Lacy MQ, Buadi F, Gertz MA, Kumar S et al. Lenalidomide plus dexamethasone vs. thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010; 115: 1343-1350.
13. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
14. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-4465.
15. Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F et al. Melphalan, prednisone and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 2009; 9: 145-150.
16. Palumbo A, Hajek R, Delforge M. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
17. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51: 1372-1383.
18. Durie BMG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
19. Cancer Therapy Evaluation Program. Common Terminology Criteria For Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS 31 march 2003 http://ctep.cancer.gov (accessed 12 December 2003).
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
22. Gay F, Rajkumar V, Falco P, Kumar S, Dispenzieri A, Petrucci MT et al. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed multiple myeloma. Eur J Haemat 2010; 85: 200-208.
23. Gay F, Haymann SR, Buadi F, Detweiler-Short K, Lacy M, Kumar S et al. Safety and efficacy of lenalidomide-dexamethasone in elderly newly diagnosed multiple myeloma patients aged 70 and older. Haematologica 2010; 95: 153 (abstract 0377).
24. Harrison SJ, Khot AS, Tsin T, Hsu A, Chen K, Loudovaris M et al. Low dose lenalidomide and dexamethasone induction followed by autologous transplantation in untreated patients with myeloma is associated with high response rates and preservation of CD8, but not CD4 or NK cellular immunity. Blood 2011; 118: 1862 (abstract 1862).
25. Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 2011; 118: 1864 (abstract 478).
26. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114: 518-521.
27. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010; 24: 1769-1778.
28. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011; 86: 640-645.